Download PDF
Semin intervent Radiol 2015; 32(01): 003-009
DOI: 10.1055/s-0034-1396956
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tumor Lysis Syndrome and Primary Hepatic Malignancy: Case Presentation and Review of the Literature

Sean P. Zivin
1   Department of Radiology, University of Illinois at Chicago, Chicago, Illinois
,
Youssef Elias
1   Department of Radiology, University of Illinois at Chicago, Chicago, Illinois
,
Charles E. Ray Jr.
1   Department of Radiology, University of Illinois at Chicago, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
02 March 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Tumor lysis syndrome (TLS) represents a constellation of laboratory and clinical derangements that can occur following treatment of malignancies with high cellular turnover. Most commonly noted in hematologic malignancies, TLS has been reported to occur following liver-directed therapy in the form of both ablative therapies and transarterial therapies. Classification schemes exist, as do established diagnostic criteria, to aid in the definitive diagnosis of TLS. In addition, treatment algorithms are reported for patients with the diagnosis of TLS. This manuscript will review the risk factors associated with the development of TLS, the diagnostic criteria used, and treatment and preventative strategies employed. In addition, an algorithm for the diagnosis and treatment of TLS will be provided.

Keywords

interventional radiology - tumor lysis syndrome - complications - chemoembolization
 

  • References

  • 1 Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008; 93 (1) 9-13
    CrossrefPubMedSearch in Google Scholar
  • 2 Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116 (8) 546-554
    CrossrefPubMedSearch in Google Scholar
  • 3 Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010; 36 (2) 164-176
    CrossrefPubMedSearch in Google Scholar
  • 4 Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol 2005; 3 (1) 54-61
    PubMedSearch in Google Scholar
  • 5 Lehner SG, Gould JE, Saad WE, Brown DB. Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 185 (5) 1307-1309
    CrossrefPubMedSearch in Google Scholar
  • 6 Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 2014; 6 (2) 5389
    PubMedSearch in Google Scholar
  • 7 McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol 2012; 5 (75) 75
    CrossrefPubMedSearch in Google Scholar
  • 8 Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364 (19) 1844-1854
    CrossrefPubMedSearch in Google Scholar
  • 9 Hsieh P-M, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol 2009; 15 (37) 4726-4728
    CrossrefPubMedSearch in Google Scholar
  • 10 Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. CMAJ 2010; 182 (15) 1631-1635
    CrossrefPubMedSearch in Google Scholar
  • 11 Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 2010; 55 (5) (Suppl. 03) S1-S13 , quiz S14–S19
    CrossrefPubMedSearch in Google Scholar
  • 12 El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Acute kidney injury associated with tumor lysis syndrome: a paradigm shift. Am J Emerg Med 2012; 30 (2) 390.e3-390.e6
    PubMedSearch in Google Scholar
  • 13 Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94 (2) 133-139
    CrossrefPubMedSearch in Google Scholar
  • 14 Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127 (1) 3-11
    CrossrefPubMedSearch in Google Scholar
  • 15 Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 2012; 7 (10) 1730-1739
    CrossrefPubMedSearch in Google Scholar
  • 16 Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 2011; 154 (1) 3-13
    CrossrefPubMedSearch in Google Scholar
  • 17 Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26 (16) 2767-2778
    CrossrefPubMedSearch in Google Scholar
  • 18 Cairo MS, Coiffier B, Reiter A, Younes A ; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149 (4) 578-586
    CrossrefPubMedSearch in Google Scholar
  • 19 Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006; 3 (8) 438-447
    CrossrefPubMedSearch in Google Scholar
  • 20 Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31 (1) 27-28
    CrossrefPubMedSearch in Google Scholar
  • 21 Sood AR, Burry LD, Cheng DK. Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy 2007; 27 (1) 111-121
    CrossrefPubMedSearch in Google Scholar
  • 22 Jeha S, Kantarjian H, Irwin D , et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19 (1) 34-38
    PubMedSearch in Google Scholar
  • 23 Burney IA. Acute tumor lysis syndrome after transcatheter chemoembolization of hepatocellular carcinoma. South Med J 1998; 91 (5) 467-470
    CrossrefPubMedSearch in Google Scholar
  • 24 Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?. Am J Med Sci 2003; 325 (1) 38-40
    CrossrefPubMedSearch in Google Scholar
  • 25 Lee CC, Wu YH, Chung SH, Chen WJ. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist 2006; 11 (1) 87-88 , author reply 89
    CrossrefPubMedSearch in Google Scholar
  • 26 Sakamoto N, Monzawa S, Nagano H, Nishizaki H, Arai Y, Sugimura K. Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma. Cardiovasc Intervent Radiol 2007; 30 (3) 508-511
    CrossrefPubMedSearch in Google Scholar
  • 27 Shiba H, Ishida Y, Wakiyama S, Sakamoto T, Misawa T, Yanaga K. Acute tumor lysis syndrome after transarterial chemoembolization for hepatocellular carcinoma. Cancer Sci 2008; 99 (10) 2104-2105
    CrossrefPubMedSearch in Google Scholar
  • 28 Huang W-S, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 2009; 15 (35) 4464-4466
    CrossrefPubMedSearch in Google Scholar
  • 29 Shiozawa K, Watanabe M, Takenaka H , et al. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology 2010; 57 (101) 688-690
    PubMedSearch in Google Scholar
  • 30 Chao CT, Chiang CK. Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report. Medical principles and practice: international journal of the Kuwait University. Health Science Centre 2012; 21 (5) 498-500E
    PubMedSearch in Google Scholar
  • 31 Nishida Y, Fujii H, Hagihara A , et al. [Tumor lysis syndrome after transarterial embolization for hepatocellular carcinoma]. Nippon Shokakibyo Gakkai Zasshi 2013; 110 (3) 441-448
    PubMedSearch in Google Scholar
  • 32 Ali AM, Barbaryan A, Zdunek T, Khan M, Voore P, Mirrakhimov AE. Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma. J Gastrointest Oncol 2014; 5 (2) E46-E49
    PubMedSearch in Google Scholar
  • 33 Kekre N, Djordjevic B, Touchie C. Spontaneous tumour lysis syndrome. CMAJ 2012; 184 (8) 913-916
    CrossrefPubMedSearch in Google Scholar
  • 34 Wang K, Chen Z. Acute tumor lysis syndrome after transarterial chemoembolization for well-differentiated hepatocellular carcinoma with neuroendocrine features. Onkologie 2010; 33 (10) 532-535
    PubMedSearch in Google Scholar
  • 35 Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004; 24 (3) 210-215
    CrossrefPubMedSearch in Google Scholar